KRONKronos Bio, Inc.

Nasdaq kronosbio.com


$ 0.95 $ -0.06 (-6.43 %)    

Tuesday, 25-Jun-2024 15:58:09 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 0.9451
$ 1.06
$ 0.00 x 0
$ 0.00 x 0
$ 0.95 - $ 1.07
$ 0.69 - $ 2.29
354,733
na
56.25M
$ 1.48
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-15-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-23-2021 12-31-2020 10-K
15 11-18-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 kronos-bio-q1-2024-adj-eps-050-misses-042-estimate-sales-2520m-beat-1000m-estimate

Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.42) ...

 hc-wainwright--co-maintains-buy-on-kronos-bio-lowers-price-target-to-225

HC Wainwright & Co. analyst Robert Burns maintains Kronos Bio (NASDAQ:KRON) with a Buy and lowers the price target from ...

 kronos-bio-to-present-clinical-update-on-phase-12-trial-of-kb-0742-at-the-2024-asco-annual-meeting

Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that...

 recap-kronos-bio-q4-earnings
Recap: Kronos Bio Q4 Earnings
03/21/2024 13:35:05

 kronos-bio-q4-eps-043-beats-052-estimate-sales-229m-beat-152m-estimate-cash-balance-of-1750m

Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.52) by...

 kronos-bio-announces-21-reduction-in-workforce-restructuring-to-focus-resources-on-clinical-development-with-extended-cash-runway-into-the-second-half-of-2026

Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new do...

 cancer-player-kronos-bio-to-stop-lanraplenib-combo-therapy-blood-cancer-study

Kronos Bio Inc (NASDAQ: KRON) says that after the review of data from the phase 1b portion of its phase 1b/2 trial of lanraplen...

 piper-sandler-maintains-overweight-on-kronos-bio-lowers-price-target-to-6

Piper Sandler analyst Edward Tenthoff maintains Kronos Bio (NASDAQ:KRON) with a Overweight and lowers the price target from ...

 uber-to-rally-over-13-here-are-10-top-analyst-forecasts-for-tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 hc-wainwright--co-maintains-buy-on-kronos-bio-lowers-price-target-to-25

HC Wainwright & Co. analyst Robert Burns maintains Kronos Bio (NASDAQ:KRON) with a Buy and lowers the price target from ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION